Skip to main content
×
×
Home

Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study

  • Jon E. Grant (a1), Brian L. Odlaug (a1), Marc N. Potenza (a2), Eric Hollander (a3) and Suck Won Kim (a1)...
Abstract
Summary

Pathological gambling is a disabling disorder experienced by about 1% of adults. We randomised 233 participants (41.6% women) 1:1:1 to nalmefene (20 or 40 mg) or placebo. In analyses performed using an intention-to-treat (ITT) population, nalmefene failed to show statistically significant differences from placebo on primary and secondary outcomes. Post hoc analyses of only participants who received a full titration of the medication for at least 1 week demonstrated that nalmefene 40 mg/day resulted in significantly greater reductions on the primary outcome measure. These findings suggest that medication dosing may be an important consideration in achieving symptom control.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about sending content to Dropbox.

      Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about sending content to Google Drive.

      Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study
      Available formats
      ×
Copyright
Corresponding author
Dr Jon E. Grant, Department of Psychiatry, University of Minnesota Medical School, 2450 Riverside Avenue, Minneapolis, MN 55454, USA. Email: grant045@umn.edu
Footnotes
Hide All

This study was funded by Somaxon Pharmaceuticals.

Declaration of interest

This study was funded by Somaxon Pharmaceuticals, and M.N.P. reports financial interests in Somaxon Pharmaceuticals; he consults for and has been an advisor to Boehringer Ingelheim; has received research support from the National Institutes of Health, Veteran's Administration, Mohegan Sun Casino, National Center for Responsible Gaming (NCRG) and Forest Pharmaceuticals. J.E.G. has received research grants from NIMH, NIDA, NCRG, Forest Pharmaceuticals and GlaxoSmithKline. E.H. has received research grants from Somaxon, Solvay and Abbott.

Footnotes
References
Hide All
1 Martin WR, Jasinski D, Mansky P. Naltrexone, an antagonist for the treatment of heroin dependence. Arch Gen Psychiatry 1973; 23: 784–89.
2 Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49: 876–80.
3 Kim SW, Grant JE, Adson DE, Shin YC. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry 2001; 49: 914–21.
4 Grant JE, Potenza MN, Hollander E, Cunningham-Williams R, Nurminen T, Smits G, et al. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry 2006; 163: 303–12.
5 Pallanti S, DeCaria CM, Grant JE, Urpe M, Hollander E. Reliability and validity of the pathological gambling adaptation of the Yale-Brown Obsessive–Compulsive Scale (PG-YBOCS). J Gambl Stud 2005; 21: 431–43.
6 Sheehan DV. The Anxiety Disease. Scribners, 1983.
7 Hollander E, Pallanti S, Allen A, Sood E, Baldini Rossi N. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? Am J Psychiatry 2005; 162: 137–45.
8 Kim SW, Grant JE, Potenza MN, Blanco C, Hollander E. The Gambling Symptom Assessment Scale (G-SAS): a reliability and validity study. Psychiatry Res 2009; 166: 7684.
9 Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38: 963–74.
10 Kim SW. Opioid antagonists in the treatment of impulse-control disorders. J Clin Psychiatry 1998; 59: 159–64.
11 Sylvain C, Ladouceur R, Boisvert JM. Cognitive and behavioral treatment of pathological gambling: a controlled study. J Consult Clin Psychol 1997; 65: 727–32.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×
Type Description Title
PDF
Supplementary materials

Grant et al. supplementary material
Supplementary Figure S1

 PDF (31 KB)
31 KB

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 3 *
Loading metrics...

Abstract views

Total abstract views: 10 *
Loading metrics...

* Views captured on Cambridge Core between 3rd January 2018 - 19th January 2018. This data will be updated every 24 hours.

Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study

  • Jon E. Grant (a1), Brian L. Odlaug (a1), Marc N. Potenza (a2), Eric Hollander (a3) and Suck Won Kim (a1)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *